Advertisement

Common Infections Following Lung Transplantation

  • Deborah J. Marriott
  • C. Orla Morrissey
Chapter

Abstract

The lungs are the only transplanted organ in direct contact with the ‘outside world’. Infection is a significant cause of morbidity and mortality in lung transplantation. Early accurate diagnosis and optimal management is essential to prevent short and long term complications. Bacteria, including Mycobacteria and Nocardia, viruses and fungi are common pathogens. Organisms may be present in the recipient prior to transplantation, transmitted with the donor lungs or acquired after transplantation. The degree of immunosuppression and the routine use of antimicrobial prophylaxis alters the pattern of post-transplant infections.

Keywords

Lung transplantation Bacterial infection Mycobacteria Respiratory virus Cytomegalovirus Infection control 

References

  1. 1.
    Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010. J Heart Lung Transplant. 2010;29:1104–18.CrossRefPubMedGoogle Scholar
  2. 2.
    Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23(2):299–323.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shields RK, Clancy CJ, Minces LR, et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant. 2012;31:1199–206.CrossRefPubMedGoogle Scholar
  4. 4.
    Hoen AG, Li J, Moulton LA, et al. Associations between gut microbial colonization early life and respiratory outcome in cystic fibrosis. J Paediatr. 2015;167:138–47.CrossRefGoogle Scholar
  5. 5.
    Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13:2601–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou J, Chen Y, Tabibi S, et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2007;51(3):1085–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009;48:1657.CrossRefPubMedGoogle Scholar
  9. 9.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266.CrossRefPubMedGoogle Scholar
  10. 10.
    Subramanian AK, Morris MI, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):68.CrossRefPubMedGoogle Scholar
  11. 11.
    Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40:990.CrossRefPubMedGoogle Scholar
  12. 12.
    Meije Y, Piersimoni C, Torre-Cisneros J, et al. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):89.CrossRefPubMedGoogle Scholar
  13. 13.
    Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276.CrossRefPubMedGoogle Scholar
  14. 14.
    Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:e1.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodrigues C, Mehta A, Jha U, Bharucha M, Dastur FD, Udwadia TE. Nosocomial Mycobacterium chelonae infection in laparoscopic surgery. Infect Control Hosp Epidemiol. 2001;22:474.CrossRefPubMedGoogle Scholar
  16. 16.
    Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381:1551.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med. 1999;160:1611.CrossRefPubMedGoogle Scholar
  18. 18.
    Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis. 2012;31:297.Google Scholar
  19. 19.
    Lee Y, Song JW, Chae EJ, et al. CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: a case-controlled comparison with immunocompetent patients. Br J Radiol. 2013;86:20120209.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367.CrossRefPubMedGoogle Scholar
  21. 21.
    Chopra S, Matsuyama K, Hutson C, Madrid P. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother. 2011;66:1533.CrossRefPubMedGoogle Scholar
  22. 22.
    Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med. 2011;105:781.CrossRefPubMedGoogle Scholar
  23. 23.
    Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant. 2006;25:985–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Lobo LJ, Chang LC, Esther CR, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transpl. 2013;27:523.CrossRefGoogle Scholar
  25. 25.
    Robinson PD, Harris KA, Aurora P, Hartley JC, Tsang V, Spencer H. Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species. Eur Respir J. 2013;41:1230.CrossRefPubMedGoogle Scholar
  26. 26.
    Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multi-drug resistant nontuberculous mycobacterium. Science. 2016;354:751.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tortoli E, Kohl TA, Trovato A, et al. Mycobacterium abscessus in patients with cystic fibrosis: low impact of inter-human transmission in Italy. Eur Respir J. 2017;50:1602525.CrossRefPubMedGoogle Scholar
  28. 28.
    Hasworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:969.CrossRefGoogle Scholar
  29. 29.
    Wlaker J, Moore G, Collins S, et al. Microbiological problems and biofilms associated with Mycobacterium chimera in heater-cooler units used for cardiopulmonary bypass. J Hosp Infect. 2017;96:209.CrossRefGoogle Scholar
  30. 30.
    Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis. 2007;44:1307.CrossRefPubMedGoogle Scholar
  31. 31.
    Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transpl. 2007;21:628.CrossRefGoogle Scholar
  32. 32.
    Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis. 2000;2:133.CrossRefPubMedGoogle Scholar
  33. 33.
    Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44:2014.Google Scholar
  34. 34.
    Kanne JP, Yandow DR, Mohammed TL. CT findings of pulmonary nocardiosis. Am J Roentgenol. 2011;197:W266.CrossRefGoogle Scholar
  35. 35.
    Clark NM, Reid GE, AST Infectious Diseases Community of Practice. Nocardia infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):83.CrossRefPubMedGoogle Scholar
  36. 36.
    Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19:259.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis. 2003;36:313.CrossRefPubMedGoogle Scholar
  38. 38.
    Welsh O, Salinas-Carmona MC, Brown-Elliott BA, et al. Disseminated actinomycetoma due to Nocardia wallacei. Int J Dermatol. 2018.  https://doi.org/10.1111/ijd.13909. [Epub ahead of print].
  39. 39.
    Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101.CrossRefGoogle Scholar
  40. 40.
    Vazquez R, Vazquez-Guillamet MC, Suarez J, et al. Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience. Transpl Infect Dis. 2015;17:259.CrossRefPubMedGoogle Scholar
  41. 41.
    Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9:1903.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors and prophylactic strategies. Transpl Infect Dis. 2001;3:161.CrossRefPubMedGoogle Scholar
  43. 43.
    Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head to head comparison to voriconazole. J Clin Microbiol. 1999;37:2343.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant. 2011;30:361.CrossRefPubMedGoogle Scholar
  45. 45.
    Husain S, Sole A, Alexander BD, et al. The 2014 International Society for Heart and Lung Transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients. J Heart Lung Transplant. 2016;35:261.CrossRefPubMedGoogle Scholar
  46. 46.
    Neoh CF, Snell GI, Levvey B, Morrissey CO, et al. Antifungal prophylaxis in lung transplantation. Int J Antimicrob Agents. 2014;44:194.CrossRefPubMedGoogle Scholar
  47. 47.
    Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258.CrossRefPubMedGoogle Scholar
  48. 48.
    Chong PP, Kennedy CC, Hathcock MA, et al. Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis. Clin Transpl. 2015;29:311.CrossRefGoogle Scholar
  49. 49.
    Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169.CrossRefPubMedGoogle Scholar
  50. 50.
    Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant. 1998;17:1029.PubMedGoogle Scholar
  51. 51.
    Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant. 2000;5:13.PubMedGoogle Scholar
  52. 52.
    Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicentre surveillance program. Med Mycol. 2005;43(Suppl 1):S49.CrossRefPubMedGoogle Scholar
  53. 53.
    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of invasive aspergillosis. 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Palmer SM, Alexander BD, Sander LL, et al. Significance of blood stream infection after lung transplantation: an analysis in 176 consecutive patients. Transplantation. 2000;69:2360.CrossRefPubMedGoogle Scholar
  55. 55.
    Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation. 2012;94:281.CrossRefPubMedGoogle Scholar
  56. 56.
    Horn DL, Neofytos D, Anaisse EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695.CrossRefGoogle Scholar
  57. 57.
    Rakvit A, Meyerrose G, Vidal AM, et al. Cellulitis caused by Cryptococcus neoformans in a lung transplant recipient. J Heart Lung Transplant. 2005;24:642.58.CrossRefGoogle Scholar
  58. 58.
    Singh N, Lotholary O, Alexander BD, et al. Immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40:1756.CrossRefPubMedGoogle Scholar
  59. 59.
    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Manchikalapati P, Canon CL, Jhala N, Eloubeidi MA. Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger’s syndrome. Dig Dis Sci. 2005;50:1181.CrossRefPubMedGoogle Scholar
  61. 61.
    Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective matched case-control study to assess risk for disease and outcome. J Infect Dis. 2009;200:1002.CrossRefPubMedGoogle Scholar
  62. 62.
    Katragkou A, Dotis J, Kotsiou M, et al. Scedosporium apiospermum infection after near-drowning. Mycoses. 2007;50:412.CrossRefPubMedGoogle Scholar
  63. 63.
    Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16:578.CrossRefPubMedGoogle Scholar
  64. 64.
    Hage CA, Ribes JA, Wengenack NL. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53:448.CrossRefPubMedGoogle Scholar
  65. 65.
    Miller R, Assi M, AST Infectious Diseases Community of Practice. Endemic fungi in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):250.CrossRefPubMedGoogle Scholar
  66. 66.
    Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807.CrossRefPubMedGoogle Scholar
  67. 67.
    Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519.CrossRefGoogle Scholar
  68. 68.
    Gigliotti F. Pneumocystis carinii: has the name really been changed? Clin Infect Dis. 2005;41:1752.CrossRefPubMedGoogle Scholar
  69. 69.
    Cushion MT, Stringer JR. Has the name really been changed? It has for most researchers. Clin Infect Dis. 2005;41:1756.CrossRefPubMedGoogle Scholar
  70. 70.
    Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098.CrossRefPubMedGoogle Scholar
  71. 71.
    Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17:770.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2003;5:84.CrossRefPubMedGoogle Scholar
  73. 73.
    Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19:39.CrossRefPubMedGoogle Scholar
  74. 74.
    de Boer MG, Bruijnesteijn van Coppenraet LE, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis. 2007;44:1143.CrossRefPubMedGoogle Scholar
  75. 75.
    Siegel JD, Rhinehart E, Jackson M, et al. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2007. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf. Accessed 25 Feb 2018.
  76. 76.
    Malkin J, Morand P, Malvy D. Seroprevalence of HSV-1 and HSV-2 in the general French population. Sex Transm Dis. 2002;78:201–3.CrossRefGoogle Scholar
  77. 77.
    Vyse A, Gay N, Slomka M. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Dis. 2000;76:183–7.CrossRefGoogle Scholar
  78. 78.
    Avery RK, Michaels RM. Update on immunisations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8(1):9–14.CrossRefPubMedGoogle Scholar
  79. 79.
    Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143(12):870–80.CrossRefPubMedGoogle Scholar
  80. 80.
    Cervera C, Marcos MA, Linares L, et al. A prospective survey of human herpes virus 6 infection in solid organ transplant recipients. Transplantation. 2006;82(7):979–82.CrossRefPubMedGoogle Scholar
  81. 81.
    Lehto JT, Halme M, Tukiainen P, et al. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant. 2007;26(1):41–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Breese Hall C. Human herpesvirus 8. In: Long S, Pickering L, Prober C, editors. Principles and practice of paediatric infectious diseases. 3rd ed. Philadelphia: Churchill Livingstone; 2008.Google Scholar
  83. 83.
    Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335(8682):123–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031.CrossRefPubMedGoogle Scholar
  85. 85.
    Bridevaux PO, Aubert JD, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69(1):32.CrossRefPubMedGoogle Scholar
  86. 86.
    Palmer SM Jr, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113(4):944.CrossRefPubMedGoogle Scholar
  87. 87.
    Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):878.CrossRefGoogle Scholar
  88. 88.
    Vilchez RA, McCurry K, Dauber J, et al. Influenza virus in solid organ transplant recipients. Am J Transplant. 2012;293:287–91.Google Scholar
  89. 89.
    Hayney MS, Welter DL, Francois M, et al. Influenza vaccine responses in lung transplant recipients. Prog Transplant. 2004;14(4):346–51.CrossRefPubMedGoogle Scholar
  90. 90.
    Zambon M, Bull T, Sadler CJ, et al. Molecular epidemiology of two outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol. 1998;36:2289.PubMedPubMedCentralGoogle Scholar
  91. 91.
    McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745.CrossRefPubMedGoogle Scholar
  92. 92.
    Principi N, Esposito S. Pediatric human metapneumovirus infection: epidemiology, prevention and therapy. J Clin Virol. 2014;59:141–7.CrossRefPubMedGoogle Scholar
  93. 93.
    Dosanjh A. Respiratory metapneumoviral infection without co-infection in association with acute and chronic lung allograft dysfunction. J Inflamm Res. 2015;8:79–82.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir Res. 2003;60(1):51–9.CrossRefPubMedGoogle Scholar
  95. 95.
    Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50(2):774–7.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Gutman JA, Peck AJ, Kuypers J, et al. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplant patients: a report of two cases. Bone Marrow Transplant. 2007;40:809.CrossRefPubMedGoogle Scholar
  97. 97.
    Kaiser L, Aubert JD, Pache JC, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174:1392.CrossRefPubMedGoogle Scholar
  98. 98.
    Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infection in T-cell depleted hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis. 2007;9:108.CrossRefPubMedGoogle Scholar
  99. 99.
    Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116:617–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Infectious Diseases and Clinical MicrobiologySt. Vincent’s Hospital, SydneyDarlinghurstAustralia
  2. 2.Medical SchoolUniversity of New South WalesSydneyAustralia
  3. 3.Department of Infectious DiseasesAlfred Health and Monash UniversityMelbourneAustralia

Personalised recommendations